Archive for January 30th, 2008

505(b)(2) - Part 3: Pre-IND submission & meeting

Before filing an IND, it is desirable (we counsel imperative) to have a pre-IND meeting with the FDA.  The goal is to get FDA’s concurrence with the proposed development plan and regulatory submission pathway.  The steps for this meeting (known as a Type B meeting) include:

Prepare a pre-IND submission package.

This package outlines where we will be [...]